search
Back to results

Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia

Primary Purpose

End Stage Renal Disease on Dialysis

Status
Active
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Whey protein supplements
Nutritional counseling
Sponsored by
Far Eastern Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Disease on Dialysis

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged greater than or equal to 20 years
  2. Having end-stage kidney disease and having undergone maintenance PD for more than three months
  3. Having adequate dialysis (weekly Kt/V greater than or equal to 1.7)
  4. Serum albumin levels lower than 4.0 g/dL, measured by bromocresol green assay

Exclusion Criteria:

  1. Untreated fluid overload
  2. Uncorrected metabolic acidosis
  3. Having active infection or inflammation
  4. Hospitalization within the past 4 weeks
  5. Having gastrointestinal bleeding
  6. those who cannot cooperate with the dietary record
  7. those who have poor adherence to whey protein consumption
  8. History of psychiatric disorders
  9. Having mental retardation

Sites / Locations

  • Far Eastern Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Nutritional counseling arm

Nutritional counseling plus whey protein supplements arm

Arm Description

Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis

Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.

Outcomes

Primary Outcome Measures

Concentrations of albumin (g/dL)
Difference in change-from-baseline albumin (g/dL) between two intervention arms

Secondary Outcome Measures

Concentrations of pre-albumin (g/dL)
Difference in change-from-baseline pre-albumin (g/dL) between two intervention arms
Concentrations of C-reactive protein (mg/dL)
Difference in change-from-baseline C-reactive protein (mg/dL) between two intervention arms
Concentrations of phosphate (mg/dL)
Difference in change-from-baseline phosphate (mg/dL) between two intervention arms
Concentrations of blood urea nitrogen (mg/dL)
Difference in change-from-baseline blood urea nitrogen (mg/dL) between two intervention arms
Concentrations of free indoxyl sulfate (mg/L)
Difference in change-from-baseline free indoxyl sulfate (mg/L) between two intervention arms
Concentrations of free p-cresol sulfate (mg/L)
Difference in change-from-baseline free p-cresol sulfate (mg/L) between two intervention arms
Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells
Difference in change-from-baseline absolute number (per μl blood) of CD4+ T cells between two intervention arms
Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells
Difference in change-from-baseline absolute number (per μl blood) of CD8+ T cells between two intervention arms
Absolute number (per μl blood) of monocytes
Difference in change-from-baseline absolute number (per μl blood) of monocytes between two intervention arms
Percentage (%) of CD4+ (cluster of differentiation 4) T cells
Difference in change-from-baseline percentage (%) of CD4+ T cells between two intervention arms
Percentage (%) of CD8+ (cluster of differentiation 8) T cells
Difference in change-from-baseline percentage (%) of CD8+ T cells between two intervention arms
Percentage (%) of monocytes
Difference in change-from-baseline percentage (%) of monocytes between two intervention arms
Lean tissue mass (kg)
Difference in change-from-baseline lean tissue mass (kg) between two intervention arms
Fat tissue mass (kg)
Difference in change-from-baseline fat tissue index (kg) between two intervention arms
Lean tissue index (kg/m2)
Difference in change-from-baseline lean tissue index (kg/m2) between two intervention arms
Fat tissue index (kg/m2)
Difference in change-from-baseline fat tissue index (kg/m2) between two intervention arms
Percentage (%) of body fat mass
Difference in change-from-baseline percentage (%) of body fat mass between two intervention arms
Percentage (%) of excess body fat
Difference in change-from-baseline percentage (%) of excess body fat between two intervention arms. Excess body fat is defined as fat percentage > 25 % for men or > 35 % for women
Percentage (%) of obesity
Difference in change-from-baseline percentage (%) of obesity between two intervention arms. Obesity is defined as body mass index > 24.

Full Information

First Posted
September 6, 2020
Last Updated
September 12, 2023
Sponsor
Far Eastern Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04546958
Brief Title
Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia
Official Title
Clinical Implication of Nutritional Counseling and Whey Protein Supplements in Patients on Peritoneal Dialysis With Hypoalbuminemia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 2, 2020 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Far Eastern Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Inadequate dietary protein intake is well-known cause of hypoalbuminemia in dialysis population. Protein loss into dialysate and increased catabolic state due to uremic milieu or inflammation worsened hypoalbuminemia, hence high protein diet is recommended in patients on peritoneal dialysis (PD). The recommendations from K/DOQI clinical practice guidelines for the amount of daily protein intake is based on expert opinion and the optimal daily protein intake in PD patients is not known. The investigators hypothesize that higher dietary protein intake has a greater beneficial effect on nutritional status in hypoalbuminemic PD patients. In particular, 1.5 g/kg protein intake provides a better beneficial effect than 1.2 g/kg protein intake.
Detailed Description
Hypoalbuminemia is common and is strongly associated with an increased risk for mortality in patients with end-stage kidney disease (ESKD). Inadequate dietary protein intake is well-known cause of hypoalbuminemia in dialysis population. Protein loss into dialysate and increased catabolic state due to uremic milieu or inflammation worsened hypoalbuminemia, hence high protein diet is recommended in PD patients. Although there is an increased daily calorie intake from absorption of dialysate glucose concentration, hypoalbuminemia ensues in a substantial number of PD patients. There is concern that a disproportionately increasing calorie intake from dialysate glucose with no change in dietary protein intake causes weight gain which in turn worsens sarcopenic obesity in PD patients. Achieving adequate dietary protein intake should be the priority in the management of hypoalbuminemia. It is feasible for PD patients to increase dietary protein intake through protein supplements. Among nutritional supplements, whey protein has several positive effects on carbohydrate metabolism, muscle building, immune function, and human health in various areas of disease, supported by well-performed studies. There are limited data available regarding the effects of nutritional counseling and whey protein supplements on the nutritional, body compositional status and immune function of PD patients with hypoalbuminemia. The recommendations from K/DOQI clinical practice guidelines for the amount of daily protein intake is based on expert opinion and the optimal daily protein intake in PD patients is not known. The aims of the study are to investigate the optimal dietary protein intake and to examine the effects of whey protein supplement on the change of nutritional, body composition and immune function in PD patients with hypoalbuminemia. Specifically, the investigators will compare the effect of nutritional counseling (1.2 g/kg protein intake) with that of nutritional counseling and whey protein supplement (1.5 g/kg protein intake) regarding the changes of nutritional, body composition parameters and immune function in PD patients. This is a quality improvement program to cope with the fact that the proportion of hypoalbuminemic PD patients sometimes does not meet the requirements set by Joint Commission of Taiwan, and to improve the nutritional status of PD patients in a feasible way of daily clinical practice. The investigators are going to conduct a randomized, controlled trial with cross-over design. Subjects with ESKD undergoing maintenance PD for more than three months, adequate dialysis, and hypoalbuminemia will be recruited. Those with non-dietary cause of hypoalbuminemia including untreated fluid overload, uncorrected metabolic acidosis, having active infection or inflammation, hospitalization within the past 4 weeks, having gastrointestinal bleeding, those who cannot cooperate with the dietary record, those who have poor adherence to whey protein consumption, history of psychiatric disorders and having mental retardation will be excluded. Participants will receive nutritional counseling with whey protein supplement or nutritional counseling alone for 3-month period, separated by 3-month washout period. The study outcome measures are difference in change-from-baseline nutritional, body composition parameters and immune function between the two study periods.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease on Dialysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
A randomized, active-controlled trial with cross-over design
Masking
Outcomes Assessor
Masking Description
Laboratory technicians who assess the study outcomes will be masked
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nutritional counseling arm
Arm Type
Active Comparator
Arm Description
Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
Arm Title
Nutritional counseling plus whey protein supplements arm
Arm Type
Experimental
Arm Description
Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey protein supplements
Intervention Description
Nutritional counseling and whey protein supplements for 3 months
Intervention Type
Other
Intervention Name(s)
Nutritional counseling
Intervention Description
Nutritional counseling by dietitians for 3 months
Primary Outcome Measure Information:
Title
Concentrations of albumin (g/dL)
Description
Difference in change-from-baseline albumin (g/dL) between two intervention arms
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Concentrations of pre-albumin (g/dL)
Description
Difference in change-from-baseline pre-albumin (g/dL) between two intervention arms
Time Frame
3 months
Title
Concentrations of C-reactive protein (mg/dL)
Description
Difference in change-from-baseline C-reactive protein (mg/dL) between two intervention arms
Time Frame
3 months
Title
Concentrations of phosphate (mg/dL)
Description
Difference in change-from-baseline phosphate (mg/dL) between two intervention arms
Time Frame
3 months
Title
Concentrations of blood urea nitrogen (mg/dL)
Description
Difference in change-from-baseline blood urea nitrogen (mg/dL) between two intervention arms
Time Frame
3 months
Title
Concentrations of free indoxyl sulfate (mg/L)
Description
Difference in change-from-baseline free indoxyl sulfate (mg/L) between two intervention arms
Time Frame
3 months
Title
Concentrations of free p-cresol sulfate (mg/L)
Description
Difference in change-from-baseline free p-cresol sulfate (mg/L) between two intervention arms
Time Frame
3 months
Title
Absolute number (per μl blood) of CD4+ (cluster of differentiation 4) T cells
Description
Difference in change-from-baseline absolute number (per μl blood) of CD4+ T cells between two intervention arms
Time Frame
3 months
Title
Absolute number (per μl blood) of CD8+ (cluster of differentiation 8) T cells
Description
Difference in change-from-baseline absolute number (per μl blood) of CD8+ T cells between two intervention arms
Time Frame
3 months
Title
Absolute number (per μl blood) of monocytes
Description
Difference in change-from-baseline absolute number (per μl blood) of monocytes between two intervention arms
Time Frame
3 months
Title
Percentage (%) of CD4+ (cluster of differentiation 4) T cells
Description
Difference in change-from-baseline percentage (%) of CD4+ T cells between two intervention arms
Time Frame
3 months
Title
Percentage (%) of CD8+ (cluster of differentiation 8) T cells
Description
Difference in change-from-baseline percentage (%) of CD8+ T cells between two intervention arms
Time Frame
3 months
Title
Percentage (%) of monocytes
Description
Difference in change-from-baseline percentage (%) of monocytes between two intervention arms
Time Frame
3 months
Title
Lean tissue mass (kg)
Description
Difference in change-from-baseline lean tissue mass (kg) between two intervention arms
Time Frame
3 months
Title
Fat tissue mass (kg)
Description
Difference in change-from-baseline fat tissue index (kg) between two intervention arms
Time Frame
3 months
Title
Lean tissue index (kg/m2)
Description
Difference in change-from-baseline lean tissue index (kg/m2) between two intervention arms
Time Frame
3 months
Title
Fat tissue index (kg/m2)
Description
Difference in change-from-baseline fat tissue index (kg/m2) between two intervention arms
Time Frame
3 months
Title
Percentage (%) of body fat mass
Description
Difference in change-from-baseline percentage (%) of body fat mass between two intervention arms
Time Frame
3 months
Title
Percentage (%) of excess body fat
Description
Difference in change-from-baseline percentage (%) of excess body fat between two intervention arms. Excess body fat is defined as fat percentage > 25 % for men or > 35 % for women
Time Frame
3 months
Title
Percentage (%) of obesity
Description
Difference in change-from-baseline percentage (%) of obesity between two intervention arms. Obesity is defined as body mass index > 24.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged greater than or equal to 20 years Having end-stage kidney disease and having undergone maintenance PD for more than three months Having adequate dialysis (weekly Kt/V greater than or equal to 1.7) Serum albumin levels lower than 4.0 g/dL, measured by bromocresol green assay Exclusion Criteria: Untreated fluid overload Uncorrected metabolic acidosis Having active infection or inflammation Hospitalization within the past 4 weeks Having gastrointestinal bleeding those who cannot cooperate with the dietary record those who have poor adherence to whey protein consumption History of psychiatric disorders Having mental retardation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wan-Chuan Tsai, M.D., Ph.D.
Organizational Affiliation
Far Eastern Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Far Eastern Memorial Hospital
City
New Taipei City
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual-level deidentified participant data will be made available by the corresponding author of the paper upon request by email. The data will be available for 3 years after formal publication.
IPD Sharing Time Frame
The data will become available after completing the study for 1 year and for 3 years after formal publication.
IPD Sharing Access Criteria
Data will be made available by the corresponding author of the paper upon request by email.

Learn more about this trial

Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia

We'll reach out to this number within 24 hrs